dc.contributor | Cláudio Antônio Bonjardim | |
dc.contributor | http://lattes.cnpq.br/9624031110564127 | |
dc.contributor | Jordana Grazziela alves Coelho dos Reis | |
dc.contributor | Edel Figueiredo Barbosa Stancioli | |
dc.contributor | José Carlos de Magalhães | |
dc.contributor | Jaquelline Germano de Oliveira | |
dc.creator | Erik Vinicius de Sousa Reis | |
dc.date.accessioned | 2022-12-29T14:49:36Z | |
dc.date.accessioned | 2023-06-16T15:16:12Z | |
dc.date.available | 2022-12-29T14:49:36Z | |
dc.date.available | 2023-06-16T15:16:12Z | |
dc.date.created | 2022-12-29T14:49:36Z | |
dc.date.issued | 2020-12-21 | |
dc.identifier | http://hdl.handle.net/1843/48509 | |
dc.identifier | https://orcid.org/0000-0001-5442-6240 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/6678407 | |
dc.description.abstract | The chikungunya virus (CHIKV) is an enveloped virus with an RNA positive
strand genome, transmitted between sperm vertebrates and arthropod vectors such
as Aedes aegypti and Aedes albopictus, comprising three genotypes. CHIKV enters
cells through clathrin-dependent endocytosis, denuding the capsid and genome and
immediately leading to the translation of the non-structural proteins that form the
replication complex termed spherules. Throughout the infection it mounts cytopathic
vacuoles, and in the final stage it is released via budding, acquiring the envelope
through the plasma membrane. There are many gaps to be explored in the CHIKV life
cycle, which can help to clarify events in the biology of the virus and support the
development of new antiviral therapies. There are no specific drugs or vaccines for
CHIKV, and there is a constant demand for the development of alternatives for the
treatment of the disease. In this work, we used biological tests, animal models,
characterization by electron, scanning, immunofluorescence and confocal
microscopy. It was shown that treatment with Trametinib at a concentration of 40 μM
reduced the viral titer by ~ 3-log, in addition to reducing the production of total viral
particles analyzed by transmission electron microscopy (MET). However, in vivo, it
was not possible to establish the immunocompetent infection model and in tests with
A129 mice Trametinib unprotected animals of CHIKV lethality. In the characterization
of the CHIKV life cycle, microscopic evidence was systematized in the references and
classic components such as: penetration via clathrin-mediated endocytosis,
production of the replication complex (spherules), production of cytopathic vacuoles
and via budding can be verified. Interestingly, in addition to the classic findings,
evidence also pointed to novel processes involved in the CHIKV multiplication cycle.
We described penetration via macropinocytosis and macropinosis formation induced
by single or multiple particles; particles enveloping through intracellular membranes
without performing budding via plasma membrane; and we showed release via
exocytosis and by protrusions of the plasma membrane, in which is suggestive of actin
tail. These findings contribute to the understanding of some obscurities related to the
CHIKV life cycle, helping the better comprehension of virus-host interactions and may
also help in the search for novel antiviral targets. | |
dc.publisher | Universidade Federal de Minas Gerais | |
dc.publisher | Brasil | |
dc.publisher | ICB - DEPARTAMENTO DE MICROBIOLOGIA | |
dc.publisher | Programa de Pós-Graduação em Microbiologia | |
dc.publisher | UFMG | |
dc.rights | Acesso Restrito | |
dc.subject | Chikungunya vírus | |
dc.subject | MEK/ERK | |
dc.subject | Antivirais | |
dc.title | Análise morfológica do ciclo de multiplicação do Chikungunya vírus e avaliação do potencial antiviral do inibidor de MEK/ERK Trametinibe (Mekinist) | |
dc.type | Tese | |